

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AJINOMOTO CO., INC.
Petitioner,

v.

ABTIS CO., LTD.
Patent Owner

Patent No. 11,896,675
Issue Date: February 13, 2024

Title: SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG
CONJUGATE AS SPECIFIC EMBODIMENT THEREOF

Inter Partes Review No. IPR2025-0283

PETITIONER'S UPDATED EXHIBIT LIST

EXHIBIT LIST

Ex #	Exhibit Description	Filed	Served
1001	U.S. Patent No. 11,896,675 (“the ’675 Patent”)	X	X
1002	Declaration of Dr. Lawrence Nathan Tumey	X	X
1003	Declaration of Dr. Tatsuya Okuzumi	X	X
1004	WO 2020/184944	X	X
1005	CA 3132959A1 (Canadian National Stage of WO 2020/184944)	X	X
1006	Yamada et al., <i>Development of a Novel Chemical Site-Specific Conjugation Platform for ADCs – Ajicap™ Technology</i> , Poster Presentation from PEP TALK 2019, THE PROTEIN SCIENCE WEEK, Jan. 14-18, 2019 (“PepTalk Poster”)	X	X
1007	Okuzumi, <i>Technology of Site Specific Conjugation for Next Generation ADCs</i> , Luncheon Presentation from PEP TALK 2019, THE PROTEIN SCIENCE WEEK, Jan. 16, 2019 (“PepTalk Presentation”)	X	X
1008	WO 2018/199337 (“Yamada”)	X	X
1009	U.S. 2020/0190165 (U.S. National Stage of Yamada)	X	X
1010	WO 2019/240288 (“Matsuda”)	X	X
1011	U.S. 2021/0139541 (U.S. National Stage of Matsuda)	X	X
1012	Clarivate Analytics, <i>PepTalk 2019 - CHI's 18th Annual Meeting - The Protein Science Week: Antibody-Drug Conjugates, San Diego, CA, USA</i> , IDDB MEETING REPORT, January 25, 2019 (“PepTalk 2019 Annual Meeting Report”)	X	X
1013	PepTalk 2019 Conference Program	X	X

Ex #	Exhibit Description	Filed	Served
1014	Croasdell, <i>18th Annual PepTalk: The Protein Science Week – Antibody-Drug Conjugates: Next-Gan Engineering</i> , DRUGS OF THE FUTURE, 2019, 44(3): 241-245	X	X
1015	Photographs from Luncheon Presentation	X	X
1016	Photographs from Poster Presentation	X	X
1017	Email exchange with Dr. Igor D'Angelo providing a copy of PepTalk Presentation	X	X
1018	Email exchange with Dr. Bernhard Valldorf providing a copy of PepTalk Presentation	X	X
1019	Email exchange with Dr. Michael Szardenings providing a copy of PepTalk Presentation	X	X
1020	Email exchange with Susan Lee providing a copy of PepTalk Presentation	X	X
1021	Email exchange with Professor Rolf G. Werner providing a copy of PepTalk Presentation	X	X
1022	LinkedIn profile of Dr. Igor D'Angelo	X	X
1023	LinkedIn profile of Dr. Bernhard Valldorf	X	X
1024	LinkedIn profile of Dr. Michael Szardenings	X	X
1025	LinkedIn profile of Susan Lee	X	X
1026	Lambert and Berkenblit, <i>Antibody–Drug Conjugates for Cancer Treatment</i> , ANNU. REV. MED., 2018, 69: 191-207.	X	X
1027	Birrer et al., <i>Antibody-Drug Conjugate-Based Therapeutics: State of the Science</i> , J. NAT'L CANCER INST., 2019, 111(6): 538-549	X	X

Ex #	Exhibit Description	Filed	Served
1028	Schumacher et al., <i>Current Status: Site-Specific Antibody Drug Conjugates</i> , J. CLIN. IMMUNOL., 2016, 36: S100-S107.	X	X
1029	Nejadmoghaddam et al., <i>Antibody-Drug Conjugates: Possibilities and Challenges</i> , AVICENNA J MED BIOTECHNOL., 2019, (1):3-23.	X	X
1030	9 th Annual World ADC Conference Program, November 12-15, 2018	X	X
1031	Mendelsohn, <i>Technology of Site Specific Conjugation for Next Generation ADCs</i> , Presentation from WORLD ADC 2018, Nov. 13, 2018	X	X
1032	Oxford English Dictionary definition of “terminal”	X	X
1033	Tam et al., <i>Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality</i> , ANTIBODIES, 2017, 6(12): 10.3390/antib6030012.	X	X
1034	Lu et al., <i>Beyond binding: antibody effector functions in infectious diseases</i> , NAT. REV. IMMUNOL., 2018, 18(1): 46–61.	X	X
1035	Prosecution History for the '675 Patent	X	X
1036	Amblard et al., <i>The Cu^I-catalyzed Huisgen 1,3-dipolar cycloaddition of azides and terminal alkynes to form 1,2,3-triazoles is the model example of a click reaction</i> , CHEM. REV., 2009, 109(9): 4207-4220.	X	X
1037	U.S. 2023/0158167 (U.S. pre-grant publication of U.S. Application 16/980,503)	X	X
1038	Japanese Patent Application No. 2018-113962	X	X
1039	Verified English Translation of Japanese Pat. App. No. 2018-113962	X	X

Ex #	Exhibit Description	Filed	Served
1040	Verified English translation of application US Ser. No. 62/815,557	X	X
1041	Tumey et al., <i>Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates</i> , AAPS JOURNAL, 2017, 19(4):1123-1135.	X	X
1042	Tumey et al., <i>Optimization of Tubulysin Antibody–Drug Conjugates: A Case Study in Addressing ADC Metabolism</i> , ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7(11): 977-982.	X	X
1043	Graziani et al., <i>PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers</i> , MOLECULAR CANCER THERAPEUTICS, 2020, 19, 10, 2068-2078	X	X
1044	Sadiki et al., <i>Site-specific conjugation of native antibodies</i> , ANTIBODY THERAPEUTICS, 2020, 3(4):271-284	X	X
1045	Chau et al., <i>Antibody–drug conjugates for cancer</i> , THE LANCET, 2019, 394(10200): 793-804.	X	X
1046	Trail et al., <i>Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design</i> , PHARMACOLOGY & THERAPEUTICS, 2018, 181: 126-142.	X	X
1047	Benjamin et al., <i>Thiolation of Q295: Site-Specific Conjugation of Hydrophobic Payloads without the Need for Genetic Engineering</i> , MOLECULAR PHARMACEUTICS, 2019, 16(6): 2795-2807.	X	X

Ex #	Exhibit Description	Filed	Served
1048	Lyon et al., <i>Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index</i> , NATURE BIOTECHNOLOGY, 2015, 33: 733-735.	X	X
1049	Staudacher & Brown, <i>Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?</i> , BRITISH JOURNAL OF CANCER, 2017, 117: 1736-1742.	X	X
1050	Pickens et al., <i>Practical Considerations, Challenges, and Limitations of Bioconjugation via Azide–Alkyne Cycloaddition</i> , BIOCONJUGATE CHEMISTRY, 2017, 29(3): 686-701.	X	X
1051	Lyon et al., <i>Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates</i> , NATURE BIOTECHNOLOGY, 2014, 32: 1059-1062.	X	X
1052	Jain et al., <i>Current ADC Linker Chemistry</i> , PHARMACEUTICAL RESEARCH, 2015, 32: 3526-3540.	X	X
1053	Knight et al., <i>Synthesis and evaluation of an 18F-labellled norbornene derivative for copper-free click chemistry reaction</i> , ORGANIC & BIOMOLECULAR CHEMISTRY, 2013, 11: 3817-3825.	X	X
1054	Oller-Salvia et al., <i>Rapid and Efficient Generation of Stable Antibody -Drug Conjugates via an Encoded Cyclopropene and an Inverse - Electron - Demand Diels -Alder Reaction</i> , ANGEW CHEM INT ED ENGL., 2018, 57(11): 2831-2834.	X	X
1055	Oliveira et al., <i>Inverse electron demand Diels–Alder reactions in chemical biology</i> , CHEMICAL SOCIETY REVIEWS, 2017, 46(16): 4895-4950.	X	X

Ex #	Exhibit Description	Filed	Served
1056	Chalker et al., <i>Methods for converting cysteine to dehydroalanine on peptides and proteins</i> , CHEMICAL SCIENCE, 2011, 2: 1666-1676.	X	X
1057	Kirmse et al., <i>Destabilisierte 2-Norbornyl-Kationen</i> , ANGEWANDTE CHEMIE, 1985, 97(1): 51-52.	X	X
1058	Mullapudi et al., <i>Resin-Supported Site-Specific Antibody Conjugation Method Leads to Antibody-Drug Conjugates with Retained Efficacy and Improved Stability</i> , BIOCONJUGATE CHEMISTRY, 2025, 36: 1956-1969.	X	X
1059	Second Declaration of Dr. Lawrence Nathan Tumey	X	X
1060	Deposition Transcript of Dr. Zhaohui Sunny Zhou	X	X
1061	Petitioner's Demonstratives	X	X

Respectfully submitted,

Dated: May 7, 2026

/Stephen B Maebius/

Stephen Maebius
Registration No. 35,264
Foley & Lardner LLP
Counsel for Petitioner

CERTIFICATE OF SERVICE

The undersigned hereby certifies that on May 7, 2026 a copy of the foregoing **PETITIONER'S UPDATED EXHIBIT LIST** was filed through PTACTs system along with email service to the email addresses listed below:

Jason Engel
jason.engel.ptab@klgates.com

Anna Hill
rebekah.hill@klgates.com

Peter Giunta
peter.giunta@klgates.com

Dated: May 7, 2026

Respectfully submitted,

- /Stephen B Maebius/

Stephen Maebius
Registration No. 35,264
Foley & Lardner LLP
Counsel for Petitioner